Skip to Main Content

Hello, everyone, and welcome to a big day in America, where some stores are reportedly sold out of ice cream and others are sold out of ammunition. As for us, we are keeping our head down and focusing on the usual tasks of foraging for interesting items. To cope, we are brewing cups of stimulation. Our choice today is blueberry, a favorite, we must confess. Meanwhile, here are some tidbits to get you going. We hope today is productive and peaceful for all concerned. And of course, stay safe — wear a mask. …

CureVac’s experimental Covid-19 vaccine triggered an immune response in humans, putting it on track to start mass testing this year as the race to end the pandemic heats up, Reuters says. The vaccine, known as CVnCoV, was generally well tolerated and trial results strongly supported the company’s plans to launch the final stage of testing involving about 30,000 participants before the end of the year. Volunteers developed a level of neutralizing antibodies on a par with people who had recovered from a serious case of Covid-19.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!